Tesamorelin/Ipamorelin: Dosage, Results and Cost (2026)

Why This Combination Exists

Of all the GH peptides, tesamorelin is the only one that the FDA has approved, and the only one with large Phase 3 trial data showing what it does to body fat. Specifically, visceral fat: the deep abdominal fat that wraps around the organs and drives metabolic disease. In two trials totaling 816 patients, CT-measured visceral fat dropped 15% in 26 weeks. A later trial showed it normalized liver fat in a third of patients. That is the reason to reach for tesamorelin over other GHRH peptides. The evidence points at one specific, measurable target: metabolic recomposition built around shrinking deep abdominal and liver fat.

This guide pairs tesamorelin with Ipamorelin, a selective GH secretagogue that adds a second, independent push on the same pituitary cells. Tesamorelin works the GHRH receptor. Ipamorelin works the ghrelin receptor and eases off the somatostatin brake, so the two together produce a larger, more synergistic GH pulse than either alone. That dual-pathway logic is the same engine behind the CJC-1295/Ipamorelin stack. Rather than restate it in full here, the CJC-1295/Ipamorelin guide walks through the gas-pedal-and-brake mechanism in detail. What sets this page apart is the GHRH component: tesamorelin instead of CJC-1295, chosen specifically for its FDA approval and its visceral-fat data.

Two Paths to the Same Problem

Tesamorelin started in Montreal. In the mid-1990s, Theratechnologies Inc. was working on a problem that had frustrated endocrinologists for decades: how to use GHRH therapeutically when the native 44-amino-acid hormone degrades in minutes. Dipeptidyl peptidase IV (DPP-IV) chews through native GHRH so fast that its plasma half-life is roughly 7 minutes. Sermorelin, a truncated 29-amino-acid GHRH fragment developed earlier, improved stability marginally but still had a short functional window.

Theratechnologies solved it by attaching a trans-3-hexenoic acid group to the N-terminal tyrosine of full-length GHRH. This single chemical modification protected the peptide from DPP-IV degradation while preserving all 44 amino acids and full receptor binding affinity. They named it tesamorelin. The clinical development program targeted HIV-associated lipodystrophy, a condition where antiretroviral therapy causes dangerous visceral fat accumulation around the organs. Two Phase 3 randomized controlled trials enrolled 816 patients. CT-measured visceral fat dropped 15% over 26 weeks. The FDA approved tesamorelin (brand name Egrifta) in November 2010. It remains the only GHRH analog with FDA approval. Read the full Tesamorelin guide for the complete clinical evidence.

Ipamorelin came from a different lab and a different decade. In the late 1990s, Novo Nordisk's peptide chemists in Denmark engineered a five-amino-acid secretagogue that triggers GH release through the ghrelin receptor without the cortisol, prolactin, or appetite spikes that plagued older compounds like GHRP-6. Raun and colleagues published it in 1998 as the first truly selective GH secretagogue. That is the Ipamorelin in both this combo and CJC-1295/Ipamorelin. The full origin story and selectivity data live in the CJC-1295/Ipamorelin guide; here the relevant point is simply that Ipamorelin is the clean amplifier bolted onto tesamorelin's GHRH signal.

What makes this pairing distinct is not the Ipamorelin half. It is the GHRH half. Tesamorelin was developed and trialed specifically to attack pathological visceral fat, and it carries an FDA approval and Phase 3 imaging data that no other GHRH peptide can claim. That is the thread that runs through the rest of this guide.

What Each Peptide Brings

The interaction goes deeper than parallel pathways. Veldhuis et al. (2009) demonstrated that co-administration of a GHRH agonist plus a ghrelin-pathway agonist produces synergistic GH secretion. The total GH output exceeds the sum of each component's individual contribution. The mechanism: Tesamorelin drives GH synthesis and release through the GHRH receptor. Ipamorelin simultaneously amplifies the pulse height through GHS-R1a activation AND suppresses somatostatin, the hypothalamic brake that would normally attenuate the GHRH signal. You get a bigger push and less resistance at the same time.

How the Pathways Converge

Key Research

Tesamorelin has the strongest clinical evidence base of any GH peptide. Ipamorelin has the cleanest selectivity data. The combination rationale rests on independent mechanistic evidence plus synergy data from GHRH + ghrelin-pathway co-administration studies.

Tesamorelin clinical evidence

Falutz J et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine, 2007. View study

The landmark trial. Two Phase 3 multicenter RCTs (LIPO-010 and LIPO-011), 816 patients with HIV lipodystrophy. CT-measured visceral adipose tissue decreased 15% over 26 weeks versus a 5% increase in placebo. Triglycerides improved. Lean mass preserved. Body image scores improved. This data earned tesamorelin its FDA approval in 2010. The sample size and imaging rigor are unusual for a peptide study.

Stanley TL et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." Lancet HIV, 2019. View study

Extended the evidence to hepatic fat. 35% of tesamorelin-treated patients normalized liver fat content versus 4% on placebo. Relevant because non-alcoholic fatty liver disease (NAFLD) affects roughly 25% of the general population, not just HIV patients. The mechanism of action (GH-mediated lipolysis) is not HIV-specific.

Ipamorelin selectivity evidence

Raun K et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998. View study

The original Novo Nordisk publication that characterized Ipamorelin's selectivity. GH release comparable to GHRP-6 in potency. No elevation of cortisol, ACTH, or prolactin, even at 200 times the effective dose. This selectivity profile distinguished Ipamorelin from every prior GH secretagogue and is the reason it became the preferred ghrelin-pathway peptide for clinical protocols.

GHRH + ghrelin-pathway synergy

Veldhuis JD et al. "Determinants of GH-releasing hormone and GH-releasing peptide synergy in men." American Journal of Physiology - Endocrinology and Metabolism, 2009. View study

This is the synergy evidence. Veldhuis demonstrated that co-administration of a GHRH agonist plus a ghrelin-pathway agonist produces GH output that exceeds the sum of individual contributions. The synergy is dose-dependent and age-modulated but consistently present. The study established the mechanistic basis for dual-pathway GH stimulation: GHRH and ghrelin act through independent receptor systems on the same somatotroph cells, and their combined activation is multiplicative, not additive.

On the combination

No large-scale randomized controlled trial has studied the specific Tesamorelin + Ipamorelin combination in a single protocol. The combination rationale rests on three pillars: (1) Tesamorelin's Phase 3 clinical data for GH-mediated metabolic improvement, (2) Ipamorelin's established selectivity profile for clean GH amplification, and (3) the Veldhuis synergy data showing that GHRH + ghrelin-pathway co-administration produces synergistic GH output. Each component is well-characterized. The convergence is mechanistically sound. But the specific pairing has not been tested in a dedicated combination trial.

When to Expect Results

GH peptide effects are cumulative. The early benefits (sleep, recovery) reflect acute GH pulse enhancement. The metabolic benefits (body composition, visceral fat) reflect sustained GH-mediated changes that build over weeks and months. The Phase 3 tesamorelin trials measured their primary endpoint at 26 weeks for a reason.

The Honest Truth

This combination pairs the most evidence-backed GH peptide with the cleanest GH secretagogue. The mechanistic rationale is strong. But there are real limitations you should understand before starting.

Tesamorelin's FDA approval is for HIV lipodystrophy only. The clinical trials were conducted in HIV patients with antiretroviral-induced visceral fat accumulation. The mechanism of action (GHRH receptor activation, GH-mediated lipolysis) is not HIV-specific. GH physiology works the same way in everyone. But the FDA indication is narrow, and using tesamorelin for body composition optimization in otherwise healthy adults is off-label. That's a distinction worth understanding.

Visceral fat returns when you stop. The Phase 3 extension data showed this clearly. Patients who discontinued tesamorelin after 26 weeks regained visceral fat over the following months. This is not a cure for body composition. It's an ongoing optimization that requires sustained or cyclical use. Plan accordingly.

No combination-specific RCT. Tesamorelin has Phase 3 data. Ipamorelin has selectivity data. The GHRH + ghrelin synergy mechanism is published. But nobody has run a dedicated trial testing this specific two-peptide combination in a single protocol with a control group. The evidence is strong at the component level. The combination logic is mechanistically sound. The specific pairing has not been independently validated.

Monitor fasting glucose. GH has counter-regulatory effects on insulin. Elevated GH can increase fasting glucose and reduce insulin sensitivity, particularly at higher doses or in individuals with pre-existing insulin resistance. Periodic fasting glucose or HbA1c monitoring is prudent during any GH-axis peptide protocol. This is not unique to this combination but it applies here.

It is not automatically the better choice. At $299/month, this combo costs the same as CJC-1295/Ipamorelin, so the decision comes down to goals rather than price. What you get for that money on the GHRH side is different: tesamorelin brings FDA approval and visceral-fat and liver-fat trial data, while CJC-1295 is the lower-data, general-purpose option. If your goal is general GH support, better sleep, and recovery, CJC-1295/Ipamorelin does that job just as well for the same cost. The case for tesamorelin is specific: you are targeting deep abdominal fat or fatty liver and you want the GHRH peptide with actual outcome data behind it.

Tesamorelin + Ipamorelin vs CJC-1295 + Ipamorelin: Which Combo For Whom

There is no separate compare page, so here is the honest decision in one place. Both combos use the same Ipamorelin. The only thing that changes is the GHRH peptide, and that single swap is what should drive your choice.

Reach for Tesamorelin + Ipamorelin when the target is fat, specifically visceral and liver fat. Tesamorelin is the only GHRH peptide with FDA approval and large Phase 3 trials, and those trials measured exactly this: CT-confirmed visceral fat down 15% in 26 weeks, liver fat normalized in roughly a third of patients. If you have stubborn deep abdominal fat, an elevated waist circumference, fatty liver, or a metabolic-syndrome profile, the evidence sits clearly with tesamorelin. The honest caveat: that FDA approval is for HIV-associated lipodystrophy, the GH-axis mechanism is not HIV-specific, and the tesamorelin-plus-Ipamorelin pairing itself has never been run in its own controlled trial.

Reach for CJC-1295 + Ipamorelin when the goal is general GH support and value matters. Its edge is convenience and cost: it is the most popular GH stack, it covers the same sleep, recovery, body-composition, and anti-aging ground that GH optimization is known for, and it costs meaningfully less per month. It carries no Phase 3 visceral-fat data because CJC-1295 was never trialed to that standard, but for someone who wants the broad benefits of better GH pulsatility without a fatty-liver or visceral-fat target, that data is not the deciding factor.

Put simply: choose tesamorelin when you want the FDA-approved, visceral-fat-proven GHRH peptide and will pay for that evidence. Choose CJC-1295 when you want broad GH support at a lower price and the deep-fat data is not your priority. Both run on the same Ipamorelin amplifier, so the synergy logic and the dosing rhythm are nearly identical either way.

Combo vs Alternatives

The most common question: how does this compare to CJC-1295/Ipamorelin and standalone Tesamorelin? Here's the honest breakdown.

Protocol

PeRx ships Tesamorelin/Ipamorelin as a single pre-mixed vial containing both peptides at calibrated concentrations. No reconstitution, no drawing from two separate vials, no mixing. One vial, one injection.

Why evening dosing matters

This isn't arbitrary timing preference. The largest natural GH pulse occurs during the first cycle of slow-wave sleep, typically 60-90 minutes after falling asleep. Injecting Tesamorelin/Ipamorelin in the evening synchronizes the peptide-stimulated GH release with this endogenous window. You're amplifying the body's own peak output rather than creating an unnatural daytime GH spike.

The empty stomach requirement is practical biochemistry. Insulin and GH are counter-regulatory. A post-meal insulin spike blunts the GH response. Waiting at least 2 hours after your last meal (ideally 3) ensures insulin is at baseline when the peptide hits.

Why cycling matters

Continuous stimulation of any receptor system causes desensitization. The pituitary downregulates GHRH and ghrelin receptors with sustained exposure, reducing peptide effectiveness over time. A 30-day washout period after 60-90 days of use allows receptor populations to normalize. When you resume, the peptides work at full potency again. This is standard receptor pharmacology.

Who This Is For

Frequently Asked Questions

Reviewed by Dr. Cory Mellon, MD · Last reviewed May 2026